AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Initially shocked that the Food and Drug Administration (FDA) denied a New Drug Application for an anti-alcohol medication that seemed destined for approval, addiction field leaders last week turned to analyzing the FDA decision's implications for future research into addiction medications.
Few experts believe the FDA's denial of the drug acamprosate will slow the pace of -- or interest in -- research into medications that could improve treatment prospects for people with alcohol dependence. Still, the decision likely means that adding a third anti-alcohol medication to the nation's treatment options is at least a few years away.
"The research is moving forward steadily, so I don't think this is going to dampen the enthusiasm of the field," Robert M. Swift, M.D., Ph.D., associate chief of staff for research and education at the VA Medical Center in Providence, R.I., told ADAW.
"This probably means just another delay in getting the research advances from the laboratory to the clients," said Swift, a faculty member at Brown University's Center for Alcohol & Addiction Studies who has written about the progress and promise of anti-addiction medications.
Forest Laboratories Inc., the pharmaceutical company that would have marketed acamprosate in the U.S. upon FDA approval, announced earlier this month that the…